Bristol Myers Squibb Gets EU Approval for Renal Cell Carcinoma Treatment
April 14 2021 - 4:58PM
Dow Jones News
By Adriano Marchese
Bristol Myers Squibb Co. said Wednesday the European Commission
has approved its drug nivolumab in combination with cabozantinib as
a treatment for patients with advanced renal cell carcinoma.
The New York-based pharmaceutical company said the approval
follows a Phase 3 trial result that showed the drug nivolumab, also
known as Opdivo, in combination with
Cabometyx--cabozantinib--significantly improved overall survival
objective response rates compared to sunitinib--another
cancer-treatment drug.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
April 14, 2021 16:43 ET (20:43 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024
